AR072795A1 - Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacion - Google Patents
Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacionInfo
- Publication number
- AR072795A1 AR072795A1 ARP090102515A ARP090102515A AR072795A1 AR 072795 A1 AR072795 A1 AR 072795A1 AR P090102515 A ARP090102515 A AR P090102515A AR P090102515 A ARP090102515 A AR P090102515A AR 072795 A1 AR072795 A1 AR 072795A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- phenofibrate
- manufacture
- capsule
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulaciones de fenofibrato con simplicidad de diseno y fabricacion y ausencia del efecto de alimentacion. La formulacion comprende fenofibrato disuelto en un tensioactivo lipofílico con el agregado opcional de un tensioactivo hidrofílico. La formulacion se puede usar en el manejo y el tratamiento de condiciones tales como hipertrigliceridemia, hipercolesterolemia y dislipidemia combinada. Proceso de fabricacion de la formulacion y formas de dosificacion que comprenden la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1384MU2008 | 2008-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072795A1 true AR072795A1 (es) | 2010-09-22 |
Family
ID=42340174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102515A AR072795A1 (es) | 2008-07-03 | 2009-07-03 | Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacion |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110160274A1 (es) |
EP (1) | EP2306989A2 (es) |
JP (1) | JP2011526621A (es) |
KR (1) | KR20110027778A (es) |
CN (1) | CN102083422A (es) |
AR (1) | AR072795A1 (es) |
AU (1) | AU2009337465A1 (es) |
BR (1) | BRPI0913940A2 (es) |
CA (1) | CA2729262A1 (es) |
MX (1) | MX2010014200A (es) |
RU (1) | RU2011103066A (es) |
WO (1) | WO2010082214A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247598A (zh) * | 2011-06-13 | 2011-11-23 | 浙江爱生药业有限公司 | 油溶性药物组合物 |
WO2013064853A1 (en) | 2011-11-05 | 2013-05-10 | Lupin Atlantis Holdings, S.A. | Reduced dose oral pharmaceutical compositions of fenofibrate |
WO2014091318A1 (en) | 2012-12-11 | 2014-06-19 | Lupin Atlantis Holdings, S.A. | Reduced dose pharmaceutical compositions of fenofibrate |
KR20230079187A (ko) | 2020-09-29 | 2023-06-05 | 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. | 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
US6814977B1 (en) * | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6719999B2 (en) * | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
EP1539117A4 (en) * | 2002-06-28 | 2005-12-14 | Shire Lab Inc | FORMULATIONS BASED ON FENOFIBRATE AND / OR FENOFIBRATE DERIVATIVES HAVING IMPROVED ORAL BIOAVAILABILITY |
US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
-
2009
- 2009-06-26 CN CN2009801259631A patent/CN102083422A/zh active Pending
- 2009-06-26 JP JP2011515736A patent/JP2011526621A/ja not_active Withdrawn
- 2009-06-26 WO PCT/IN2009/000365 patent/WO2010082214A2/en active Application Filing
- 2009-06-26 RU RU2011103066/15A patent/RU2011103066A/ru not_active Application Discontinuation
- 2009-06-26 KR KR1020117000785A patent/KR20110027778A/ko not_active Application Discontinuation
- 2009-06-26 BR BRPI0913940A patent/BRPI0913940A2/pt not_active IP Right Cessation
- 2009-06-26 EP EP09838194A patent/EP2306989A2/en not_active Withdrawn
- 2009-06-26 CA CA2729262A patent/CA2729262A1/en not_active Abandoned
- 2009-06-26 US US13/002,372 patent/US20110160274A1/en not_active Abandoned
- 2009-06-26 AU AU2009337465A patent/AU2009337465A1/en not_active Abandoned
- 2009-06-26 MX MX2010014200A patent/MX2010014200A/es not_active Application Discontinuation
- 2009-07-03 AR ARP090102515A patent/AR072795A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20110160274A1 (en) | 2011-06-30 |
CN102083422A (zh) | 2011-06-01 |
MX2010014200A (es) | 2011-03-21 |
EP2306989A2 (en) | 2011-04-13 |
WO2010082214A2 (en) | 2010-07-22 |
AU2009337465A1 (en) | 2010-07-22 |
RU2011103066A (ru) | 2012-08-10 |
JP2011526621A (ja) | 2011-10-13 |
BRPI0913940A2 (pt) | 2015-10-20 |
WO2010082214A3 (en) | 2010-10-28 |
KR20110027778A (ko) | 2011-03-16 |
CA2729262A1 (en) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021000789A2 (es) | Composiciones farmacéuticas que comprenden meloxicam | |
CO2019008364A2 (es) | Composiciones farmacéuticas que comprenden meloxicam | |
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
CR20170361A (es) | Forma de dosificación que incluye una solución sólida de drogas amorfas | |
CO6480985A2 (es) | Formulaciones para el tratamiento del dolor tisular profundo | |
CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
ECSP14013160A (es) | Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu | |
SV2009002857A (es) | Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo | |
CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
CL2014000623A1 (es) | Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades. | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
ES2616035T3 (es) | Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica | |
CL2015002817A1 (es) | Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
AR072795A1 (es) | Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacion | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
CL2016001130A1 (es) | Composiciones sólidas de triglicéridos y usos de estas | |
DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
AR095220A1 (es) | Conjunto para un dispositivo de administración de fármacos | |
AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
ECSP15033649A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
AR095194A1 (es) | Conjunto para un dispositivo de administración de fármacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |